FDA Webview

Free FDA Notices

Advisory Panels to Discuss Neuropsychiatric Effects of Smoking Cessation Therapies


Federal Register Notice: FDA will hold a meeting 9/14 of the Psychopharmacologic Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The meeting will be held from 8 a.m. to 5 p.m. FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, the Great Room (Rm. 1503), Silver Spring, MD. The committees will discuss a completed postmarketing-requirement randomized, placebo controlled trial of the neuropsychiatric effects of Chantix (varenicline), Zyban (bupropion), and nicotine replacement therapy, along with relevant published observational studies to determine whether the findings support changes to product labeling. Contact Kalyani Bhatt, (301) 796-9001. To view this notice, click here.